

Workstream 3: AMC surveillance



WHO strategy for surveillance of use of antimicrobials



Twofold approach for measuring the use of antimicrobials in countries

- Antimicrobial consumption
- Routine surveillance
- Target: Manufacturers/Distributors
- Estimate which antimicrobials are used and how much
- Census data
- National ⇒ Facility









- Target: patients, prescribers, dispensers
- Understand how antimicrobials are used
- Sample data










Flexibility of data sources along the medicines value chain



Monitoring antimicrobial consumption



National surveillance

- Provide estimates on types and quantities used at country level
- Targets: national policies, regulations, rational use, supply


Data providers











Facility surveillance

- Provide estimates on types and quantities used at facility level
- Targets: national/facility policies, supply, stewardship

Data providers







Stepwise approach to AMC data collection




To ensure all countries can measure their use of antimicrobials to some degree

Country based surveillance program

Fully aggregated	Health sectors	Health levels
	National Regional	
	Annually Quarterly	

Hospital based surveillance program



- Balance between objectives and available resources
- Depends on availability of data, IT infrastructure, manpower




GLASS Guide for national surveillance of AMC at hospital level


GLASS Global Antimicrobial Resistance and Use Surveillance System

Summary of feedback on methodological approach

- Separation of inpatient/outpatient data in countries at hospital level
 - 75% Yes
 - Comments:
 - Heterogeneity of hospitals and IT solutions, case by case
 - Private sector involvement
- Availability and level of dispensing data in hospitals
 - 90% Ward dispensation
 - Comments:
 - Some countries reports that ward information is reported on the individual patient purchase/prescription



Separation inpatients/outpatients data




Ward dispensation/Patient individual purchase data World

GLASS Guide for national surveillance of AMC at hospital level



Summary of feedback on tools

- Practical tools
 - ->80% Yes, the WHO guide is a practical tool
 - Comments:
 - Consumption calculation:
 - having tools to calculate consumption
 - centralized vs decentralized calculation
 - Adding concrete examples
 - Coordination tools
 - IT solutions



Practical tools



Discussion points




Methodological questions

- Feedback: most of countries replied that inpatients / outpatients consumption data are separated.
 - Q1: Can inpatients / outpatients consumption data be easily extracted on routine basis?
 - Yes or Yes in selected facilities
 - If Yes, what allows you to do so, what is your experience?
 - If No, what are the barriers, what would be needed to extract the data separately on routine basis?
- Feedback: most of countries replied that ward dispensations is the main option for dispensation in hospitals
 - Q2: Can this be done on routine basis?
 - Q3: For countries that use the inpatients direct purchasing from hospital pharmacy
 - Can you capture individual purchase data and aggregate them by wards/departments and inpatients/outpatients?
 - Can you capture data on purchase/dispensing of antimicrobials outside the hospital?

2. Additional tools for surveillance of antimicrobial consumption

- IT needs: data computation, transfer, reporting
- Tools (survey, questionnaires) for deep dive (supply / shortage, prescribing vs dispensing, inpatients / outpatients consumption, in/out hospital dispensing...)





WHO Guide on use of data - Under development-

- Advocacy

- Inform R&D

Inform global EMLMonitor global trends

- Monitor AWaRe indicators

- Assess effectiveness & inform actions



Objectives

to provide a framework for using and considering quality-assured AMRU surveillance data to inform strategies and action to tackle AMR

Structure

- Facility/National
- Hospital/Primary care
- AMR / AMC data

Content

- Domain
- Data needed
- Analyses
- Indicators or metrics
- Limitations, Requirements and biases
- Target audience

consumption Antimicrobial

National Level

Global Level

 Inform the development, implementation, monitoring and evaluation of national goals and policies to control AMR.

Inform national EML, regulatory and procurement policies

Assess effectiveness of & inform actions

- Inform empiric patient treatment


- Inform infection prevention and control strategies
- Inform antimicrobial stewardship initiatives and service provision
 - Inform quality of prescribing practice, antimicrobial sales, drug availability and affordability in primary care

Local level

Domains of interest for surveillance of antimicrobial use



Antimicrobial stewardship



Antimicrobial use data



Antimicrobial resistance




Antimicrobial use in other sectors



Integrated approach for optimal use of antimicrobials



- Surveillance of antimicrobial use and consumption is part of a broader, formal framework
- Data needs to be shared and analyzed based on objectives and target audience
- Surveillance data sharing could be passive (like a repository of data: users request data) or can be active (data are proposed to users)
- Upstream discussion between data providers and data users needs to happen in order to collect the right data to answer actual needs





Discussion points



- Domains of interest
 - Which domains are you working on?
 - What are the bottlenecks to work on the proposed domains? What is needed for overcoming them?
 - What are your country experiences?

Integrated approach

- Do you have formal collaboration (NAP, Access to Medicines, Disease programs, Strengthening pharmaceutical systems, UHC)?
- Which groups participants you are working with? Any outcome, impact?
- What are the facilitators or bottlenecks for collaboration?





Drug utilization and the ATC/DDD system



- Surveillance of antimicrobial use/consumption IS drug utilization
- The ATC/DDD system is the basis for AMC
 - ATC: Codification of antimicrobial medicines
 - DDD: metrics for consumption
 - To ensure standardization and comparability
- Globally, is the level of knowledge on these notions adequate for AMC?


Looks not!



- Lack in education (university degree, professional trainings)
- Too complicated (even high-income countries have difficulties)?
- Solutions:
 - Better training
 - Automatization
 - Alternatives?



Q4: Are hospital pharmacists in your country knowledgeable on ATC/DDD system to undertake AMC monitoring in facilities?





Areas for support



- Feedback from countries based on the online questionnaire
- 3 areas identified
 - 1. Support on surveillance program
 - Technical
 - Protocols, Data collection and analysis
 - Financial
 - IT equipment in facilities
 - 2. Tools
 - Directed to the surveillance program (e.g., software for AMC/DDD calculation...)
 - Improving health information systems (e.g., HIS, electronic patient databases...)
 - 3. Support on use of surveillance data, integration, NAP implementation
- Under which umbrella at national level these AMC/AMU activities are implemented in countries?
 - AMR, Access to medicines, Pharmaceutical Systems, Disease Programs, Universal Health Coverage



How to provide country support



- Development of additional tools / guidance
- Training
 - Online training / course
 - WHO Online course on AMC / WHO Academy course on surveillance of AMR and AMC / WHO ATC DDD Toolkit
 - Physical workshops
 - Education
 - Improve curriculum content
 - Professional training
- Activity support
 - Workshops
 - Remote support / helpdesk
- Networking
 - Community of practice / WHO regional networks / Academia
- Coordination of support among donors/groups
 - Structure/Body for international support coordination at country level
 - Integration to general frameworks for support:
 - AMR, Access to medicines, Pharmaceutical Systems, Disease Programs, Universal Health Coverage



Discussion points



1. Drug utilization and ATC/DDD

What would be your solutions to improve knowledge on these notions among health professionals?
 Short term / Long term solutions

2. Support on surveillance of antimicrobial use and consumption

- Online training
- Networks
 - Are you part of international networks, which ones? What about WHO regional network on AMU?
- Donors/Partners coordination
 - Will upstream coordination between partners/donors on country support for surveillance of AMC at global or regional level facilitate your work at national level?

